Modulation of Hyperandrogenic Anovulation Through Fenugreek Seeds

NCT07586969 | Completed DMC

• 1 other identifier: IRB-UOL-FAHS/930/2023
• Study Type: interventional
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

Hyperandrogenic anovulation is a common gynecological illness that impacts the ovaries, vagina and uterus. According to Statistics, in Pakistan 17.6% of individuals seeking treatment at infertility clinics were found to be affected by hyperandrogenic anovulation. Studies indicate that fenugreek seeds have the potential to improve insulin sensitivity, control hormone levels, namely the increased androgens linked to hyperandrogenic anovulation, and promote ovulation, a process commonly interrupted in individuals with hyperandrogenic anovulation. In order to create a therapy plan that is both affordable and easily accessible for women who suffer from hyperandrogenic anovulation, this study aims to determine the therapeutic efficacy of fenugreek seed powder in reducing symptoms related to the illness. Furthermore, it aims to increase knowledge on the extensive utilization of fenugreek seed powder as a natural treatment for hyperandrogenic anovulation.

Conditions

Poly Cystic Ovary Syndrome

Keywords

hyperandrogenic Anovulation.; Fenugreek (Trigonella foenum-graecum L.); Insulin Resistance

Outcome Measures

Primary Outcomes (1)

• FSH/LH Test

  Ratio of Follicle Stimulating Hormone (FSH) to Luteinizing Hormone (LH)

  2 months

Study Arms (3)

Control group

ACTIVE COMPARATOR

• Control group (G0): Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast prescribed by doctor.

Drug: Control

fenugreek seeds low dose

EXPERIMENTAL

3gram/ half teaspoon fenugreek seeds powder

Dietary Supplement: Fenugreek seeds (G1):

Fenugreek seeds high dose

EXPERIMENTAL

6gram/ one teaspoon fenugreek seeds

Dietary Supplement: Fenugreek seeds (G2)

Interventions

Control DRUG

Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast for the duration of 02 months.

Control group

Fenugreek seeds (G1): DIETARY_SUPPLEMENT

Participants were advised to take 3g/half teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 month.

fenugreek seeds low dose

Fenugreek seeds (G2) DIETARY_SUPPLEMENT

Participants were advised to take 6g/one teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 months.

Fenugreek seeds high dose

Eligibility Criteria

• Age: 15 Years - 25 Years
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Female have been BMI more than 25
• Patients with irregular periods or hormonal imbalance
• Patients with age 15 to 25 years of young females

You may not qualify if:

• Pregnant \& Lactating Women
• Any history of allergic reaction to fenugreek seeds
• Severe gastrointestinal disorders like crohn's disease
• People with liver or kidney issue

Sponsors & Collaborators

• University of Lahore: lead

Study Sites (1)

Punjab medical center, jail road, Lahore

Lahore, 54000, Pakistan

Location

Related Publications (1)

• Swaroop A, Jaipuriar AS, Gupta SK, Bagchi M, Kumar P, Preuss HG, Bagchi D. Efficacy of a Novel Fenugreek Seed Extract (Trigonella foenum-graecum, Furocyst) in Polycystic Ovary Syndrome (PCOS). Int J Med Sci. 2015 Oct 3;12(10):825-31. doi: 10.7150/ijms.13024. eCollection 2015.

  PMID: 26516311 RESULT

Related Links

• Related Info

MeSH Terms

Conditions

Insulin Resistance

Condition Hierarchy (Ancestors)

Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Head University Institute of Diet and Nutritional Sciences

Model Details: Randomized Controlled Trial

Study Record Dates

• First Submitted: July 31, 2025
• First Posted: May 14, 2026
• Study Start: September 11, 2024
• Primary Completion: November 11, 2024
• Study Completion: December 11, 2024
• Last Updated: May 28, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share

Locations

PA (1)